SPACInsider Logo
Tortoise Acquisition Corp. Files for $225M SPAC IPO
by Kristi Marvin on 2019-02-06 at 10:02pm

Wednesday evening, we had a new SPAC IPO filing in the form of the $225 million Tortoise Acquisition Corp.  Tortoise is being led by Vincent Cubbage, as CEO, President and Chairman of the Board of Directors. Most recently, Mr. Cubbage was the former CEO of Lightfoot Capital Partners GP LLC, and is currently a Managing Director, Private Energy, of Tortoise Capital Advisors, L.L.C., since January 2019.

This is an interesting SPAC for a number of reasons, but first and foremost is the fact that Barclays is on the cover as a new entrant in the SPAC underwriting game.  Plus, Barclays decided to debut with Goldman Sachs and UBS as its joint bookrunners (however, Barclays is still left lead).  That’s a solid line-up of tier-1 banks, but will Barclays need to lean on Goldman and UBS as a SPAC newbie?  Remains to be seen…SPACs are harder than they look.

Regardless, this SPAC’s structure has a few bells and whistles to boot, but let’s start with the basics.  First off, this is a 100% in trust, 24 months deal, but with 1/2 warrant in its unit, not 1/3.  Plus, Tortoise has added the option of calling the warrants for shares at $10.00.  This feature is typically seen (so far) in tier-1 SPACs and means that while the company can call the warrants post-combination for cash or cashless exercise at $18.00, they can also call them for redemption for shares at $10.00 or greater.  The amount of shares an investor will receive in the call for shares scenario is based on a black scholes model that has calculated the fair market value based on the time and price at which they are called. We’ve discussed the merits of this term before and you can read about that here.

Additionally, you will also see the appearance of the Crescent Term once again and just like in the Deutsche Bank deals of  RMG and DiamondPeak, Tortoise is using a threshold of $9.20 before they will reset the warrant strike in the event of a PIPE done below $10.00 at combination.  The use of $9.20, rather than $9.50 (seen in Megalith, EdTechX, etc.) appears to be a way of distinguishing the tier-1 deals from the rest of the pack.  In the parlance of the sub-35 year old crowd, “you can’t sit with us”.

Lastly, Tortoise has added a forward purchase agreement for $150 million from Atlas Point Energy Infrastructure Fund, LLC (“Atlas Point Energy”), but there is an added twist.  Typically, a forward purchase agreement is done at $10.00 per unit. However, in Tortoise’s forward purchase, the SPAC team has the option of allowing Atlas Point Energy to purchase either units at $10.00 or just shares at $9.67 – the choice is at Tortoise’s discretion at the time of the business combination.  Generally, post-unit split of a SPAC IPO of this structure, $9.67 is where the share would trade anyway, but the optionality for management to decide which they would like Atlas to purchase is a nice feature.

All told, this is a pretty good structure and the 1/2 warrant feels appropriate and sell-able. Plus, the Crescent Term and $150 million Forward Purchase add a little gravy to this meal.  It’s all about the roadshow now and how the team performs.

Summary of terms below:

Tortoise terms 2-6-19

Barclays Capital Inc., Goldman Sachs & Co. LLC and UBS Securities LLC are joint book-running managers.
Vinson & Elkins L.L.P. and Skadden, Arps, Slate, Meagher & Flom LLP are issuer’s counsel and underwriter’s counsel, respectively.

 

Recent Posts
by Marlena Haddad on 2023-01-27 at 11:34am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...

by Nicholas Alan Clayton on 2023-01-27 at 10:00am

Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change.  However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...

by Kristi Marvin on 2023-01-27 at 7:33am

Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...

by Nicholas Alan Clayton on 2023-01-27 at 7:30am

In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...

by Marlena Haddad on 2023-01-26 at 5:32pm

Seaport Calibre Materials Acquisition Corp. (Nasdaq: SCMA) announced this afternoon that it is pushing today’s special meeting back until January 31. The SPAC is currently facing a completion deadline of February 1, but is looking to extend its timeline by an additional six months to August 1. Stockholders may elect to redeem their shares for a pro rata...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved